Part 4: Advanced-Stage and Relapsed/Refractory Hodgkin Lymphoma

Jasleen Randhawa, MD

Fellow, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Sai Ravi Pingali, MD

Fellow, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Timothy S. Fenske, MD

Associate Professor of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Question 5

Which of the following novel agents is not known to have any activity against refractory Hodgkin lymphoma?

  •   Brentuximab vedotin
  •   Bortezomib
  •   Everolimus
  •   Lenalidomide
  •   Rituximab

Updated 10/01/2012 • jdw | Copyright ©2014 Turner White Communications